EP

Press release - EP President Metsola at EUCO: The Single Market is Europe’s greatest economic driver

Retrieved on: 
Thursday, April 18, 2024
European Parliament, Electricity, European banking union, Hamas, Democracy, European Council, Islam, Special, Travel, Human, AI, Digital Markets Act, Poverty, Parliament, Capital market, Investment, European, Future, Security, Single market, EP, Reform, Work, SME, EUCO, Digital Services Act, Renewable energy

Doubling down on the Single Market ensures Europe’s long-term competitiveness, prosperity and leadership on the global stage, said President Metsola at the Special European Council. Source : © European Union, 2024 - EP

Key Points: 


Doubling down on the Single Market ensures Europe’s long-term competitiveness, prosperity and leadership on the global stage, said President Metsola at the Special European Council. Source : © European Union, 2024 - EP

CathVision to Present Predictive Filtering Capabilities of ECGenius System at EHRA 2024

Retrieved on: 
Monday, April 8, 2024
Ghent University, Freedom, PVI, Noise, Vein, Patient, University, EP, Artifact, PV, Extended play, Electronics

COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System's predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures. The data will be presented in a poster presentation at EHRA 2024.1

Key Points: 
  • COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System's predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures.
  • Key data points include:
    Of the 68 veins treated, 33 exhibited power line noise on one or more bipolar traces during the freeze cycle (49%).
  • "When we employed the predictive filter using the ECGenius System, the noise was eliminated from the electrogram data during the PVI procedure.
  • For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at EHRA 2024, please contact us and connect on LinkedIn .

Press release - LUX Award: invitation to interview the nominees on 16 April in Brussels

Retrieved on: 
Tuesday, April 9, 2024
Smoke, European Parliament, Civil service commission, Partnership, Teacher, Accreditation, Interview, LUX, Fallen Leaves, Adamant, System, European Film Academy, Actor, European, European Commission, Cultural diversity, EP, Lux Prize, Bee, Cinema of Europe, Film industry

LUX Award: invitation to interview the nominees on 16 April in Brussels

Key Points: 
  • LUX Award: invitation to interview the nominees on 16 April in Brussels
    On the day of the ceremony, journalists will be able to interview representatives of the five films shortlisted for the 2024 LUX European Audience Film Award.
  • The interviews would take place on 16 April at the European Parliament.
  • Press conference
    Immediately after the ceremony (around 19.15) a press conference with the winner will take place in Parliament’s Anna Politkovskaya press conference room (SPAAK 0A50).
  • Ceremony
    The winner of the LUX European Audience Film Award will be announced on 16 April at 18.00 in the hemicycle of the European Parliament in Brussels.

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

Lil Mosey Goes Independent, Inks Deal with Cinq Music for Highly Anticipated New Project

Retrieved on: 
Wednesday, March 20, 2024
Entrepreneurship, Music, Partnership, News, Hitmaker, Record, GoDigital, Cinq Music Group, EP, Cinq, Lil Mosey, Hardship, Lil

Cinq Music, the leading indie distributor, record label and publisher, whose diverse artist repertoire includes some of the most legendary creators across hip hop/R&B as well as culturally significant performers in Latin music, is set to amplify Lil Mosey to connect with and expand his global fanbase.

Key Points: 
  • Cinq Music, the leading indie distributor, record label and publisher, whose diverse artist repertoire includes some of the most legendary creators across hip hop/R&B as well as culturally significant performers in Latin music, is set to amplify Lil Mosey to connect with and expand his global fanbase.
  • “Lil Mosey is a true superstar,” said Barry Daffurn, Cinq President and Co-Founder.
  • For Lil Mosey, joining forces with Cinq Music represents one such new beginning.
  • “I was excited to bring this deal between Lil Mosey and Cinq together.

Nationwide RIA EP Wealth Advisors Builds on California Presence with Acquisition of Central Coasts’ Wacker Wealth Partners

Retrieved on: 
Tuesday, April 2, 2024
Consulting, Accounting, Professional Services, Finance, Organization, Growth, Partnership, Acquisition, RIA, RIAS, EP, Wealth, Financial adviser

EP Wealth Advisors , a leading independent registered investment adviser (“RIA”) with an expanding national presence and client base, has acquired Wacker Wealth Partners, LLC (“Wacker”).

Key Points: 
  • EP Wealth Advisors , a leading independent registered investment adviser (“RIA”) with an expanding national presence and client base, has acquired Wacker Wealth Partners, LLC (“Wacker”).
  • The partnership with the San Luis Obispo, California-based firm expands EP’s presence in California to the state’s Central Coast and adds nearly $1.2B in assets under management.
  • The added depth and breadth of services available as part of EP were key to making the decision to partner with a nationwide firm.
  • “The Wacker team places client service above all other goals, which is just one of the many attributes we share,” said Ryan Parker, CEO of EP Wealth Advisors.

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the European Patent Office

Retrieved on: 
Tuesday, April 2, 2024
Salt, Progression-free survival, Patient, EPO, MD, Pembrolizumab, Human, Therapy, European Patent Convention, Safety, Pharmacokinetics, Randomized controlled trial, Patent, EP, Animal, SRR, Pharmaceutical industry

HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.

Key Points: 
  • European Patent 3,823,617 Issued on March 6, 2024
    HADDONFIELD N.J., April 2, 2024 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European Patent Office (EPO) issued EP patent 3,823,617 ('617 patent) covering the pharmaceutical composition of matter for the company's lead compound, LNS8801.
  • "We are extremely pleased that the EPO has issued this composition of matter patent," commented Patrick Mooney, MD, CEO of Linnaeus.
  • As we continue to collect very promising data from our clinical trials with LNS8001, we will continue to prosecute the claims in this patent worldwide."
  • The study will enroll 135 patients who will be selected based on a predictive biomarker and then randomized to receive LNS8801 alone, LNS8801 and pembrolizumab, or physician's choice therapy.

PrepMD and Magnifi Group Launch Annual EP Course for Fellows and Young Attendings

Retrieved on: 
Friday, March 22, 2024
Partnership, History, MD, EP, Wolpe, Cardiac electrophysiology, Nursing

BRAINTREE, Mass., March 22, 2024 /PRNewswire/ -- PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP) Fellows and Young EP Attendings course .

Key Points: 
  • BRAINTREE, Mass., March 22, 2024 /PRNewswire/ -- PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP) Fellows and Young EP Attendings course .
  • Renowned Electrophysiologist Vivek Reddy, MD will lead the course, supported by an estimated ten distinguished EP specialists.
  • Andrew Wolpe, President/COO of Magnifi Group, anticipates a promising launch of the EP Fellows Program with PrepMD's collaboration.
  • It is available to 2nd-year EP fellows and 1st and 2nd-year attendings, with limited spots for 55 attendees.

Bound2B successfully obtains preliminary injunction against Xolution Germany GmbH and its re-sealable XO closing device on beverage cans

Retrieved on: 
Thursday, March 21, 2024
Federal Patent Court, District court, Injunction, XO, Judgement, European Patent Convention, Patent, EP, Court

RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.  The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.

Key Points: 
  • in particular its XO closing device, in Germany
    RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.
  • The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.
  • In 2020, Bound2B initiated patent infringement proceedings before the District Court of Düsseldorf based on EP 930 against Xolution GmbH, who manufactured, advertised, and delivered the XO closing device.
  • In order to prevent further offering and selling of the XO closing device in Germany, Bound2B filed for urgent proceedings and asked the Düsseldorf Court to immediately issue a preliminary injunction against Xolution Germany GmbH as well as its Managing Director, Mr. von Rettberg.

Bound2B successfully obtains preliminary injunction against Xolution Germany GmbH and its re-sealable XO closing device on beverage cans

Retrieved on: 
Thursday, March 21, 2024
Federal Patent Court, District court, Injunction, XO, Judgement, European Patent Convention, Patent, EP, Court

RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.  The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.

Key Points: 
  • in particular its XO closing device, in Germany
    RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.
  • The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.
  • In 2020, Bound2B initiated patent infringement proceedings before the District Court of Düsseldorf based on EP 930 against Xolution GmbH, who manufactured, advertised, and delivered the XO closing device.
  • In order to prevent further offering and selling of the XO closing device in Germany, Bound2B filed for urgent proceedings and asked the Düsseldorf Court to immediately issue a preliminary injunction against Xolution Germany GmbH as well as its Managing Director, Mr. von Rettberg.